HPV Vaccination and the Risk of Invasive Cervical Cancer

This nationwide Swedish cohort study evaluated the association between quadrivalent HPV vaccination and the risk of invasive cervical cancer among 1,672,983 girls and women aged 10–30 years from 2006 to 2017. During follow up, cervical cancer was diagnosed in 19 vaccinated women (cumulative incidence: 47 per 100,000) and 538 unvaccinated women (94 per 100,000). After adjustment for covariates, the incidence rate ratio was 0.37 (95% CI, 0.21–0.57) for vaccinated versus unvaccinated women. Vaccination before age 17 showed the strongest protective effect (incidence rate ratio: 0.12; 95% CI, 0.00–0.34). The study concludes that quadrivalent HPV vaccination is associated with a substantially reduced risk of invasive cervical cancer, particularly when administered at younger ages. These findings support global HPV vaccination programs as a critical strategy for cervical cancer prevention.

This nationwide Swedish cohort study evaluated the association between quadrivalent HPV vaccination and the risk of invasive cervical cancer among 1,672,983 girls and women aged 10–30 years from 2006 to 2017. During follow up, cervical cancer was diagnosed in 19 vaccinated women (cumulative incidence: 47 per 100,000) and 538 unvaccinated women (94 per 100,000). After adjustment for covariates, the incidence rate ratio was 0.37 (95% CI, 0.21–0.57) for vaccinated versus unvaccinated women. Vaccination before age 17 showed the strongest protective effect (incidence rate ratio: 0.12; 95% CI, 0.00–0.34). The study concludes that quadrivalent HPV vaccination is associated with a substantially reduced risk of invasive cervical cancer, particularly when administered at younger ages. These findings support global HPV vaccination programs as a critical strategy for cervical cancer prevention.